Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of Ent001 in healthy adults
NL-OMON51546Phase 1Recruiting
- Sponsor
- Enthera Pharmaceuticals
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ebrasodebart in diabetes mellitus type 1 (T1D) and autoimmune colitis (5 cohorts), sponsored by Enthera Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jan 2023; status: recruiting.
02
Drugs
Ebrasodebart
03
Conditions
diabetes mellitus type 1 (T1D)autoimmune colitis
Beyond the preview
Go deeper on NL-OMON51546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51546.